News & Publications

WilmerHale Represents Fulcrum Therapeutics in $80 Million Series B

  • 9.5.2018

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an $80 million Series B financing. The financing was led by Foresite Capital.

The WilmerHale team representing Fulcrum in this transaction included Lia Der Marderosian, Stephanie Singer and Andrea Sorrentino.

Fulcrum’s press release is available at